Lumos Pharma, Inc. Profile Avatar - Palmy Investing

Lumos Pharma, Inc.

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phas…

Biotechnology
US, Austin [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Lumos Pharma, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of LUMO's Analysis
CIK: 1126234 CUSIP: 55028X109 ISIN: US55028X1090 LEI: - UEI: -
Secondary Listings
LUMO has no secondary listings inside our databases.